Inflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCU

Zabana Abdo, Y.Marin-Jimenez, I.Rodriguez-Lago, I.Ramirez Estesos, E.Meijilde, S.Ramos, L.Gomollon, E.Munoz, E.Suris, G.Ortiz de Zarate, J.Huguet, J. M.Llao, J.Garcia-Sepulcre, M.Sierra, M.Dura, M.Estrecha, S.Fuentes Coronel, A.Hinojosa, E.Olivan, L.Iglesias, E.Gutierrez, A.Varela, P.Rull, N.Gilabert, P.Hernandez-Camba, A.Brotons, A.Ginard, D.Sese, E.Carpio, D.Aceituno, M.Cabriada, J. L.Gonzalez-Lama, Y.Jimenez, L.Chaparro, M.Lopez-San Roman, A.Alba, C.Plaza-Santos, R.Piqueras, M.Domenech, E.Esteve, M.COVID-19-Ell Consortium ENEIDA2025-01-072025-01-072021-05-011873-9946https://hdl.handle.net/10668/25522enInflammatory Bowel Disease (IBD) and immunosuppression do not worsen the prognosis of COVID-19. Results from the ENEIDA Project of GETECCUconference outputopen access10.1093/ecco-jcc/jjab076.7291876-4479https://academic.oup.com/ecco-jcc/article-pdf/15/Supplement_1/S553/38320923/jjab076.729.pdf709432400730